Access brought to you by: LOCKSS

Lipid Disorders

Empagliflozin Improves Glycemic Parameters and Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus
Lifestyle Intervention Fails to Reduce Rate of CV Events in T2DM but Has Favorable Effect on other Measures
Statin Use Improves Respiratory-Related Mortality in Patients with COPD
HPS2-THRIVE: Niacin Fails to Show Benefit in Patients at High Risk of Vascular Events
High-Dose Rosuvastatin Reduces Contrast-Induced Nephropathy
Novel Therapeutics May Lower LDL in Familial Hypercholesterolemia
Human Monoclonal Antibody for PCSK9 Lowers Cholesterol and Is Well Tolerated
Effects of 12 Weeks of Treatment with RN316 (PF-04950615) in Hypercholesterolemic Subjects on High and Maximal Dose Statins
Bioresorbable Drug-Eluting Scaffolds: A New Treatment Paradigm for Atherosclerotic Plaque
HPS2-THRIVE Results

Pages